BiondVax's Universal Flu Vaccine Recieves Additional US Patent

Broadens BiondVax’s global intellectual property portfolio

NESS ZIONA, ISRAEL, January 27, 2016 - 

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled “Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines” has completed examination and is allowed for issuance as a patent.

The invention covers the use of BiondVax’s universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax’s completed clinical trials have shown significantly increased effectiveness against multiple flu strains.   

Ron Babecoff, CEO of BiondVax commented, “Current flu vaccines are strain specific and are not particularly effective against circulating ‘wild-type’ strains due to mismatches. In fact, last year’s seasonal flu vaccine was only 23% effective¹. Conversely, our vaccine provides long-lasting and higher effectiveness against multiple flu strains.”

Continued Dr. Babecoff, “Our newly approved US patent demonstrates the novel nature of our vaccine technology and strengthens our IP portfolio for many years to come.”

About BiondVax Pharmaceuticals Ltd.BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.

¹ http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm

BiondVax Pharmaceuticals Ltd. Announces Closing of U.S. Initial Public Offering

Nes Ziona, Israel, May 15, 2015 – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of its previously announced U.S. initial public offering of 1,910,000 American Depositary Shares (ADSs), each ADS representing 40 of its ordinary shares, and warrants to purchase up to an aggregate of 1,910,000 ADSs at an offering price of $5.00 per ADS and $0.01 per warrant. In addition, the underwriter has partially exercised their option to purchase an additional 128,000 warrants to purchase 128,000 ADSs. The warrants have a per ADS exercise price of $6.25, are exercisable immediately and will expire on May 15, 2020. Gross proceeds to BiondVax from this offering are approximately $9.57 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by BiondVax.Aegis Capital Corp. acted as the sole book-running manager for the offering.A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission on May 11, 2015.A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC’s web site at http://www.sec.gov.  Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

BiondVax to Initiate the Process for Trading the Company's Shares in the US through ADR

Nes Ziona, Israel – April 1, 2014 – BiondVax Pharmaceuticals Ltd (TASE: BNDX), developer of a universal flu vaccine, announced today that its Board of Directors has approved initiation of the process for listing the Company's shares for trading in the US through American Depository Receipt (ADR).The Company will act to register an ADR Level 1 Over-The-Counter (OTC), which does not include the option for public offerings in the US (without additional registration). The Company’s key goals are to increase the visibility of the Company and its game changing technology to the public and analysts globally, facilitate access to professional and institutional investors, increase the volume of trading and, more generally, maximize its value for shareholders.Dr. Ron Babecoff, BiondVax’s CEO: "So far, the universal flu vaccine being developed by the Company was demonstrated to be safe and active against seasonal and pandemic flu strains in four human clinical trials, and to match newly emerging strains. Now, as we focus on seeking commercial agreements with governments around the world or strategic partners, we have decided to make our shares accessible also to US investors and broaden awareness of BiondVax’s successes."